Which problems can be solved with ProNexibus Plus®?

The electromedical device Pronexibus Plus® has been used effectively to treat practically any musculoskeletal problem, on every body district.

Moreover, thanks to its anti-inflammatory and anti-edema effect, the Pronexibus Plus® can be used with benefit also in the context of rheumatological-inflammatory pathologies and for functional recovery after traumas (both iatrogenic – e.g. orthopedic surgery – and accidental).

What patients can I treat with Pronexibus Plus®?

Over the years we have gained considerable experience with the electromedical device Pronexibus Plus® in the treatment of every kind of patient: from the fragile elderly patient to the elite sportsman.

Thanks to the collaborations with the Universities of Padua and Verona, no adverse reactions were detected either during or after the treatment, and there was no pharmacological interaction with the typical polytherapies of older patients.

What are the advantages of the Pronexibus Plus®?

The strengths of the Pronexibus Plus® are touched by hand since the very first sessions:

• The clinical benefit is already evident after the first sessions, both from the patient and the operator.
• The Pronexibus Plus® is very easy to use to manage during treatment.
  
• You don’t need neither gels nor creams.
  
• You don’t need physical work from the operator.
• It can be used both in a static and dinamic (sliding the handpiece) way.

How and why the ProNexibus Plus® work?

The electromedical device Pronexibus Plus® allows to obtain exceptional therapeutic effects thanks to the biological activity, both direct and indirect, of high frequencies.

The microcirculation^1,2 is the anatomical-functional substrate where our electromedical device acts: the high frequencies allow to reach deep into the tissues by targeting with therapy directly the site of the lesion – e.g. the belly of a muscle, the fracture area of a bone, the damaged nerve.

At the site of the lesion, the capacitive high frequencies diathermic treatment with Pronexibus Plus® induces the development of a massive blood flow³which, with a wash-out mechanism, allows the effective removal of tissue “waste products” (tissue catabolites). In this way, proinflammatory cytokines and chemokines are removed and, at the same time, all the metabolites necessary to the tissue are brought to the site in order to recover its physiological function.

Capacitive diathermy also has a direct effect on immune function^4–6, inducing a physiological self-balancing according to the needs of the tissue, and acts directly on nerve receptors involved in pain perception pathways (TRPV3-4)^7,8  to “turn them off”.

Hence, this is how the ProNexibus Plus® therapeutical effects develop:

• Antiinflammatory: direct effect on leukocytes and reduction of proinflammatory metabolites.
• Painkiller/Antalgic: reduction of pro-antalgic chemokines and direct effect on pain receptors.
  
• Anti-edema: The hyperinflow of blood reduces the hydrostatic pressure within the capillary (venturi effect).
  
• Proregenerative: the massive influx of nutrients brought to the site supplies the “gasoline” necessary for tissue regeneration/ physiological repair.

References

1. Guven, G., Hilty, M. P. & Ince, C. Microcirculation: Physiology, Pathophysiology, and Clinical Application. Blood Purif. 49, 143–150 (2020).
2. Secomb, T. W. & Pries, A. R. The microcirculation: physiology at the mesoscale: The microcirculation: physiology at the mesoscale. J. Physiol. 589, 1047–1052 (2011).
3. Joyner, M. J. & Casey, D. P. Regulation of Increased Blood Flow (Hyperemia) to Muscles During Exercise: A Hierarchy of Competing Physiological Needs. Physiol. Rev. 95, 549–601 (2015).
4. Mace, T. A. et al. Differentiation of CD8 ⁺ T cells into effector cells is enhanced by physiological range hyperthermia. J. Leukoc. Biol. 90, 951–962 (2011).
5. Evans, S. S., Repasky, E. A. & Fisher, D. T. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat. Rev. Immunol. 15, 335–349 (2015).
6. Díaz, F. E. et al. Fever-range hyperthermia improves the anti-apoptotic effect induced by low pH on human neutrophils promoting a proangiogenic profile. Cell Death Dis. 7, e2437–e2437 (2016).
7. Moran, M. M., McAlexander, M. A., Bíró, T. & Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov. 10, 601–620 (2011).
8. Tansey, E. A. & Johnson, C. D. Recent advances in thermoregulation. Adv. Physiol. Educ. 39, 139–148 (2015).